Empagliflozin — Drug Intelligence | 45 EU Trials

Filter these 45 trials by condition, phase, country and more.

Open in Search →

45 Registered trials

17 Recruiting

20 Completed trials

38 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 16 Phase II/III: 1 Phase II: 11 Phase I/II: 1 Phase III/IV: 2 Phase IV: 13 Other: 1

Oversight events:

2 temporary halts across 2 trials

View oversight register →

Indications tested

Diabetes mellitus 2 Chronic kidney disease 2 Acute myocardial infarction 2 Monogenic diabetes 1 Acute kidney injury 1 Aortic valve replacement 1 Aortic stenosis 1 Type 2 diabetes mellitus 1 Albuminuria 1 Portal hypertension 1 Cardiogenic shock 1

Sponsors using this IMP

Boehringer Ingelheim International GmbH 6 Boehringer Ingelheim Espana S.A. 4 Centre Hospitalier Universitaire De Nantes 2 Universitair Medisch Centrum Groningen 2 Ziekenhuis Oost Limburg 2 Andrea Di Marco 1 Bayer AG 1 Celltrion Inc. 1 Center For Outcomes Research And Clinical Epidemiology S.r.l. 1 CHRU De Nancy 1 Colorado Prevention Center 1 Eli Lilly & Co. 1

All trials

45 total

Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure Pending

2024-513799-16-00 Phase IV 1 country Ziekenhuis Oost Limburg
Reducing Non-Alcoholic Steatohepatitis Pending

2024-518334-88-00 Phase IV 1 country Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha
EValuating the Effect of periopeRaTIve sodium-Glucose cOtransporter 2 inhibitors on cardiac surgery associated acute kidney injury: the VERT… Pending

2024-519997-37-00 Phase III 1 country Hospital Clinico Universitario De Valladolid
Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20] Pending

2025-522119-41-00 Phase III 1 country Centre Hospitalier Universitaire De Nice
Sodium-glucose cotransporter-2 inhibitors to stabilize coronary ather-osclerosis progression after acute myocardial infarction in women and … Pending

2025-523375-29-00 Phase III 1 country Humanitas Mirasole S.p.A.
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes Pending

2025-524395-30-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
The GranStone Trial Pending

2026-525608-85-00 Phase II/III 1 country Region Hovedstaden
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting

2025-520660-18-00 Phase IV 1 country Policlinico San Donato S.p.A.
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi… Recruiting

2025-521780-12-00 Phase III/IV 1 country Andrea Di Marco
the EMPOWER Study Recruiting

2023-508610-42-00 Phase II 2 countries Universitaetsspital Basel
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone… Recruiting

2024-513416-98-00 Phase II 2 countries Karolinska University Hospital
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) Recruiting

2025-523743-35-00 Phase II 1 country Universitair Medisch Centrum Groningen
A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission. Recruiting

2025-522560-32-01 Phase IV 1 country Ziekenhuis Oost Limburg
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATI… Recruiting

2023-508874-27-00 Phase III 1 country Colorado Prevention Center
A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting

2024-512577-27-00 Phase III 10 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute d… Recruiting

2024-517977-26-00 Phase III 1 country Friedrich-Schiller-Universitaet Jena
SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting

2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Phase III 23 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Phase III 12 countries Boehringer Ingelheim International GmbH
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Phase III 3 countries Medical University Of Graz
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejectio… Recruiting

2023-503602-37-00 Phase III 1 country CHRU De Nancy
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Phase III 11 countries Boehringer Ingelheim International GmbH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardioto… Recruiting

2024-515495-13-00 Phase III 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting

2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG

Showing 1–24 of 45 trials

← All drugs A–Z